 Kyle Annen
Concepts (70)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hematopoietic Stem Cell Transplantation | 2 | 2022 | 670 | 0.940 |
Why?
| | ABO Blood-Group System | 1 | 2025 | 53 | 0.880 |
Why?
| | Blood Transfusion | 2 | 2025 | 395 | 0.850 |
Why?
| | Peripheral Blood Stem Cells | 1 | 2022 | 4 | 0.780 |
Why?
| | Blood Donors | 2 | 2021 | 115 | 0.780 |
Why?
| | Neuroacanthocytosis | 1 | 2022 | 5 | 0.760 |
Why?
| | Granulomatous Disease, Chronic | 1 | 2022 | 49 | 0.740 |
Why?
| | Antibodies, Viral | 4 | 2021 | 654 | 0.690 |
Why?
| | Blood Component Removal | 1 | 2021 | 28 | 0.690 |
Why?
| | Convalescence | 1 | 2021 | 19 | 0.680 |
Why?
| | Immunotherapy, Adoptive | 2 | 2021 | 358 | 0.610 |
Why?
| | Antibodies, Neutralizing | 2 | 2021 | 321 | 0.590 |
Why?
| | Hematologic Neoplasms | 1 | 2021 | 159 | 0.590 |
Why?
| | Cannabis | 1 | 2021 | 510 | 0.420 |
Why?
| | Child | 6 | 2025 | 22390 | 0.240 |
Why?
| | Neoplasms | 1 | 2021 | 2731 | 0.230 |
Why?
| | Immunoassay | 2 | 2021 | 110 | 0.210 |
Why?
| | Antigens, Viral | 2 | 2021 | 179 | 0.200 |
Why?
| | Hematopoietic Stem Cell Mobilization | 1 | 2022 | 27 | 0.190 |
Why?
| | Antigens, CD34 | 1 | 2022 | 88 | 0.190 |
Why?
| | Blood Volume | 1 | 2022 | 65 | 0.190 |
Why?
| | Bone Marrow Transplantation | 1 | 2022 | 292 | 0.180 |
Why?
| | Vero Cells | 1 | 2021 | 87 | 0.170 |
Why?
| | Emergency Responders | 1 | 2021 | 37 | 0.170 |
Why?
| | Reagent Kits, Diagnostic | 1 | 2020 | 34 | 0.160 |
Why?
| | Cell- and Tissue-Based Therapy | 1 | 2021 | 82 | 0.160 |
Why?
| | Leukapheresis | 1 | 2020 | 26 | 0.160 |
Why?
| | Child, Preschool | 3 | 2025 | 11511 | 0.160 |
Why?
| | Immunoglobulin G | 2 | 2021 | 882 | 0.160 |
Why?
| | Clinical Laboratory Techniques | 1 | 2020 | 96 | 0.160 |
Why?
| | Time Factors | 2 | 2021 | 6951 | 0.150 |
Why?
| | Humans | 12 | 2025 | 141284 | 0.150 |
Why?
| | Insurance Coverage | 1 | 2020 | 239 | 0.140 |
Why?
| | Betacoronavirus | 1 | 2020 | 277 | 0.130 |
Why?
| | Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2020 | 288 | 0.130 |
Why?
| | Pneumonia, Viral | 1 | 2020 | 374 | 0.110 |
Why?
| | Adolescent | 3 | 2025 | 22116 | 0.110 |
Why?
| | Coronavirus Infections | 1 | 2020 | 370 | 0.110 |
Why?
| | Colorado | 2 | 2021 | 4599 | 0.110 |
Why?
| | Wounds and Injuries | 1 | 2021 | 917 | 0.100 |
Why?
| | Infant, Newborn | 1 | 2025 | 6270 | 0.100 |
Why?
| | Immunization, Passive | 2 | 2022 | 88 | 0.090 |
Why?
| | Male | 3 | 2025 | 70140 | 0.090 |
Why?
| | Infant | 1 | 2025 | 9820 | 0.080 |
Why?
| | Treatment Outcome | 2 | 2022 | 11216 | 0.080 |
Why?
| | Female | 3 | 2025 | 75814 | 0.080 |
Why?
| | Spike Glycoprotein, Coronavirus | 2 | 2021 | 123 | 0.080 |
Why?
| | Adult | 2 | 2022 | 39319 | 0.070 |
Why?
| | Surveys and Questionnaires | 1 | 2021 | 5948 | 0.070 |
Why?
| | Pregnancy | 1 | 2021 | 7035 | 0.070 |
Why?
| | United States | 1 | 2025 | 15298 | 0.070 |
Why?
| | Sensitivity and Specificity | 2 | 2021 | 1973 | 0.060 |
Why?
| | Young Adult | 1 | 2021 | 13727 | 0.050 |
Why?
| | Pandemics | 2 | 2021 | 1655 | 0.050 |
Why?
| | Cross Reactions | 1 | 2021 | 132 | 0.040 |
Why?
| | Microspheres | 1 | 2021 | 140 | 0.040 |
Why?
| | Seroepidemiologic Studies | 1 | 2021 | 170 | 0.040 |
Why?
| | Nucleocapsid Proteins | 1 | 2020 | 27 | 0.040 |
Why?
| | Serologic Tests | 1 | 2020 | 54 | 0.040 |
Why?
| | ROC Curve | 1 | 2021 | 594 | 0.040 |
Why?
| | Injury Severity Score | 1 | 2021 | 570 | 0.040 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2021 | 849 | 0.040 |
Why?
| | Resuscitation | 1 | 2021 | 295 | 0.040 |
Why?
| | Plasma | 1 | 2020 | 222 | 0.040 |
Why?
| | Animals | 1 | 2021 | 37328 | 0.040 |
Why?
| | Phosphoproteins | 1 | 2020 | 332 | 0.030 |
Why?
| | RNA, Viral | 1 | 2020 | 695 | 0.030 |
Why?
| | Hemorrhage | 1 | 2021 | 788 | 0.030 |
Why?
| | Reproducibility of Results | 1 | 2021 | 3345 | 0.020 |
Why?
| | Prospective Studies | 1 | 2022 | 7805 | 0.020 |
Why?
|
|
Annen's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|